Are hyperintense signal increases on cranial MRI a new finding for differential diagnosis in rheumatic diseases?

Yıl 2025, Cilt: 15 Sayı: 3, 295 - 301, 15.09.2025

Ayşe Eda Parlak , Esra Taşkıran

https://doi.org/10.16919/bozoktip.1732421

Öz

Objective:
To retrospectively evaluate demographic and clinical features of patients with rheumatic diseases, analyze cranial magnetic resonance imaging (MRI) findings taken for various reasons, and assess their contribution to diagnosis.
Methods:
Thirty-eight patients followed for rheumatologic diseases between March 2023 and December 2024 were included. Cranial MRI scans performed for reasons such as headache, vertigo, migraine, and cerebrovascular events were reviewed. Hyperintense signal changes were assessed on T2-weighted and Fluid Attenuation Inversion Recovery (FLAIR) images, including lesion location, number, and morphology.
Results:
Of the 38 patients, 22 had Rheumatoid Arthritis (RA), 4 had Sjögren’s syndrome, 9 had Systemic Lupus Erythematosus (SLE), 2 had SLE with multiple sclerosis (MS), and 1 had Ankylosing Spondylitis (AS). Cranial lesions were observed in 32 cases (84.2%). Lesions were most common in RA (18 patients, 81.8%), with 88.9% showing periventricular localization. Among RA patients, 8 had periventricular-cortical/subcortical, 4 had periventricular-juxtacortical, and 2 had only periventricular lesions. In the SLE group, lesions were present in 8 patients (88.8%), and in both SLE-MS cases (100%), all with periventricular localization. Of these, 4 had periventricular-cortical/subcortical and 2 had periventricular-juxtacortical involvement.
Conclusion:
Cranial MRI findings may support diagnosis and symptom evaluation in rheumatic diseases. Nonspecific hyperintense signals, particularly with periventricular distribution, may reflect early central nervous system (CNS) involvement and aid differential diagnosis.

Anahtar Kelimeler

Rheumatic diseases , cranial mrı , hyperintense lesions , differential diagnosis , central nervous system involvement , white matter lesions

Etik Beyan

The study was approved by the University of Health Sciences Antalya Training and Research Hospital ethics committee (Approval date and number: 2025/121)

Destekleyen Kurum

yok

Teşekkür

yok

Kraniyal MRG'de hiperintens sinyal artışları, romatizmal hastalıkların ayırıcı tanısında yeni bir bulgu mudur?

Öz

Amaç:
Romatizmal hastalığı olan hastaların demografik ve klinik özelliklerini geriye dönük olarak değerlendirmek, farklı nedenlerle çekilen kranial manyetik rezonans görüntüleme(MRG) bulgularını analiz etmek ve bu bulguların tanıya katkısını araştırmak.
Yöntemler:
Mart 2023- Aralık 2024 tarihleri arasında romatolojik hastalıklar nedeniyle takip edilen 38 hasta çalışmaya dahil edildi. Baş ağrısı, vertigo, migren ve serebrovasküler olay gibi nedenlerle çekilen kranial MRG görüntüleri değerlendirildi. T2 ağırlıklı ve FLAIR (Fluid Attenuation Inversion Recovery) sekanslarında izlenen hiperintens sinyal değişiklikleri; lezyonun yerleşimi, sayısı ve morfolojik özellikleri açısından incelendi.
Bulgular:
38 hastanın 22’si Romatoid Artrit (RA), 4’ü Sjögren sendromu, 9’u Sistemik Lupus Eritematozus (SLE), 2’si SLE-Multipl Skleroz (MS) ve 1’i Ankilozan Spondilit (AS) tanılıydı. Toplam 32 hastada (%84,2) kranial lezyon saptandı. RA’lı 18 hastanın %88,9’unda periventriküler yerleşimli lezyonlar izlendi. Bunların 8’i periventriküler-kortikal/subkortikal, 4’ü periventriküler-juxtakortikal ve 2’si sadece periventriküler yerleşimliydi. SLE grubunda 8 (%88,8), SLE-MS grubunda ise 2 (%100) hastada lezyon saptandı ve tamamı periventriküler yerleşimliydi. Bu lezyonların 4’ü periventriküler-kortikal/subkortikal, 2’si periventriküler-juxtakortikaldi.
Sonuç:
Kranial MRG bulguları, romatizmal hastalıklarda tanı, semptom değerlendirmesi ve ayırıcı tanıya katkı sağlayabilir. Özellikle periventriküler yerleşimli nonspesifik hiperintens sinyaller, erken santral sinir sistemi tutulumunu gösterebilir.

Anahtar Kelimeler

Romatizmal hastalıklar , ,kraniyal MRG , ,hiperintens lezyonlar , ,ayırıcı tanı , ,merkezi sinir sistemi tutulum , ,beyaz madde lezyonları

Kaynakça

• 1. Bougea A, Anagnostou E, Spandideas N, Triantafyllou N, Kararizou E. An update of neurological manifestations of vasculitides and connective tissue diseases: a literature review. Einstein (Sao Paulo). 2015;13(4):627-35.
• 2. Kandemirli SG, Bathla G. Neuroimaging findings in rheumatologic disorders. J Neurol Sci. 2021;427:117531.
• 3. Resende ABL, Monteiro GP, Ramos CC, Lopes GS, Broekman LA, De Souza JM. Integrating the autoimmune connective tissue diseases for the medical student: A classification proposal based on pathogenesis and clinical phenotype. Heliyon. 2023;9(6):e16935.
• 4. Strunk D, Schmidt-Pogoda A, Beuker C, Milles LS, Korsukewitz C, Meuth SG, et al. Biomarkers in Vasculitides of the Nervous System. Front Neurol. 2019;10:591.
• 5. Cox JG, de Groot M, Cole JH, Williams SCR, Kempton MJ. A metaanalysis of structural MRI studies of the brain in systemic lupus erythematosus (SLE). Clin Rheumatol. 2023;42(2):319-26.
• 6. Manolios E, Manolios N, Spencer D. Leptomeningitis in rheumatoid arthritis. Eur J Rheumatol. 2021;8(1):48-50.
• 7. Karathanasis DK, Rapti A, Nezos A, Skarlis C, Kilidireas C, Mavragani CP, et al. Differentiating central nervous system demyelinating disorders: The role of clinical, laboratory, imaging characteristics and peripheral blood type I interferon activity. Front Pharmacol. 2022;13:898049.
• 8. Filippi M, Rocca MA, Ciccarelli O, de Stefano N, Evangelou N, Kappos L, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016;15(3):292- 303.
• 9. Juncker AS, Appenzeller S, de Souza JM. Central Nervous System Involvement in Systemic Autoimmune Rheumatic Diseases-Diagnosis and Treatment. Pharmaceuticals (Basel). 2024;17(8):1044.
• 10. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-73.
• 11. Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N, et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain. 2019;142(7):1858-75.
• 12. Galbusera R, Bahn E, Weigel M, Cagol A, Lu PJ, Schaedelin SA, et al. Characteristics, prevalence, and clinical relevance of juxtacortical paramagnetic rims in patients with multiple sclerosis. Neurology. 2024;102:e207966.
• 13. Solomon AJ, Naismith RT, Cross AH. Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice. Neurology. 2019;92(1):26-33.
• 14. Wildner P, Stasiołek M, Matysiak M. Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases. Mult Scler Relat Disord. 2020;37:101452.
• 15. Cohen D, Rijnink EC, Nabuurs RJ, Steup-Beekman GM, Versluis MJ, Emmer BJ, et al. Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement. Rheumatology (Oxford). 2017;56(1):77-86.
• 16. Pasoto SG, Chakkour HP, Natalino RR, Viana VS, Bueno C, Lianza AC, et al. Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren's syndrome. Clin Rheumatol. 2012;31(9):1331-8.